Sanofi looks to cell culture tech for universal flu vaccine

By Dan Stanton contact

- Last updated on GMT


Related tags: Influenza vaccine, Vaccine

Sanofi Pasteur has licensed SK Chemicals' mammalian cell culture platform for vaccine production in a deal worth up to $155m (€126m).

The mammalian cell culture technology is used to make SK Chemicals’ commercial trivalent and quadrivalent seasonal influenza vaccines, and now Sanofi will use it as part of its own influenza vaccine development programme.

“SK Chemical has proven its competitive development capability in the cell culture technology currently used in quadrivalent influenza vaccine, among others, and is equipped with a world-standard production facility and capacity,”​ Sanofi spokesperson Laurence Bollack told Biopharma-Reporter.

The Korean conglomerate was the first to commercialise a quadrivalent – stimulating an immune response against four different antigens – cell culture-based flu vaccine when it launched SKYCellflu in the local market last year, and now Sanofi hopes the tech can be used to produce a universal flu vaccine.

“Sanofi Pasteur is actively exploring several innovative influenza vaccine technologies for the future. This includes the development of a broadly protective influenza vaccine that will be designed to protect against influenza without the need to manufacture and administer a vaccine every season,”​ said Bollack.

Under the terms of the deal, Sanofi will pay the Korean vaccine maker an upfront payment of $15m, plus a further $20m once the technology is transferred. Potential milestone payments could be worth as much as $120m.

Cells, insects and eggs

Bollack added the technology will complement recent investments in influenza vaccines, which includes €170m for a VaxigripTetra production facility​ in France and the $650m acquisition of Protein Sciences​.

VaxigripTetra is a influenza vaccine containing two A strains (A/H1N1 and A/H3N2) and two B strains (B/Victoria and B/Yamagata), but unlike SK Chemicals’ quadrivalent vaccine it is made via the traditional method of growing the live virus in hen eggs.

Making vaccines in eggs has certain drawbacks, namely the risk of infection, issues with supply and the length of time needed for production which can be several times longer than with cell-based systems.

Protein Sciences, meanwhile, has a quadrivalent vaccine approved (FluBlok) which uses an insect virus-based expression system to make large quantities of viral hemagglutinin, the protein that elicits the strongest immune response. The firm has previously said​ it can make a flu vaccine in two-three months, compared with six months using hen eggs.

Related topics: Upstream Processing, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us


View more